ADMA Q4 2023 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$74M+47.9% YoY

Gross Profit

$31M42.1% margin

Operating Income

$14M19.3% margin

Net Income

-$18M-23.9% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

+9.9%

Cash Flow

Operating Cash Flow

$18M

Free Cash Flow

$16M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$329M

Total Liabilities

$194M

Stockholders' Equity

$135M

Cash & Equivalents

$51M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$74M	$50M	+47.9%
Gross Profit	$31M	$14M	+119.3%
Operating Income	$14M	-$6M	+334.9%
Net Income	-$18M	-$12M	-44.3%

Revenue Segments

ADMA BioManufacturing Segment

$52M99%

Plasma Collection Centers Segment

$488,7631%